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In patients with chronic renal failure undergoing regular hemodialysis (HD), oxidative stress is involved in the development of dialysis-
related pathologies. The aim of the study was to measure the effect of HD treatment on the general antioxidative status of serum with special
consideration of the specific oxidizability of lipids and proteins.
Indicators for the oxidative/antioxidative status of plasma were monitored at the beginning and at the end of a dialysis session on the
arterial and venous side of the dialyzer. A decrease in the antioxidant status was accompanied by an increased oxidizability of proteins as well
as lipids during HD treatment. During the first passage of the dialyzer, the lag time of lipid oxidation decreased from 114.0F 19.8 to
81.5F 18.9 min, the lag time of protein oxidation decreased from 105.0F 24.6 to 72.9F 21.3 min and the total antioxidative status
decreased from 518F 24 to 252F 124 AM trolox equivalents. The carbonyl content of serum proteins was high in patients with end stage
renal disease (ESRD) (3.9F 1.1 vs. 0.9F 0.1 nmol/mg in controls) but did not change significantly during dialysis procedure.
Our data demonstrate that the susceptibility of serum lipids and proteins to oxidative modification is severely increased by HD treatment.D 2003 Elsevier B.V. All rights reserved.Keywords: Hemodialysis; End stage renal disease; Antioxidant; Free radical; Oxidative stress1. Introduction
There is wide agreement that patients undergoing regular
dialysis treatment experience increased oxidative stress
[1,2]. The lines of evidence range from increased stimula-
tion of neutrophiles [3,4], elevated serum concentrations of
lipid peroxidation products [5,6], impairment of the antiox-
idant system [7–9], endothelial dysfunction [9], to increased
modification of proteins [10]. However, the sources and
mechanisms of elevated oxidative damage remain a matter
of controversy. Some authors provide evidence that dialysis
treatment is the main source of increased oxidative damage
in patients with end stage renal disease (ESRD) [7,9,11].
Others discuss the disease itself as the main reason for
elevated oxidative stress [12,13]. The methods used for the
determination of oxidative stress are generally of a broad
range. An often used and easily detectable parameter for the0925-4439/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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(TAS) [14]. However, this value is predominately caused by
the uric acid and protein content of serum [15]. As these
values are disturbed in ESRD patients, TAS has to be
interpreted with care especially concerning ESRD patients
[16–18]. On the other hand, as uric acid and protein
contribute to the antioxidative property of serum, TAS could
be a valuable tool to follow changes during the dialysis
treatment. Moreover, there are conflicting results concerning
the antioxidative status of serum from ESRD patients.
Impairment of the antioxidant system as well as an increased
antioxidative status were reported, obviously depending also
on the method used [7,8,17–22].
The oxidizability of serum components provides an
easily accessible parameter for determining antioxidative
properties of serum. However, measuring oxidation of
isolated serum components may lead to an underestimation
of antioxidative capacities due to the loss of antioxidants
during preparation. Therefore, the measurement of oxidiz-
ability of serum components in the whole serum is a
convenient and reliable alternative allowing a measurement
in a less artificial environment [23,24]. Further problems
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idant to use and, on the other hand, the oxidizability of the
target molecule [24].
This study was intended to follow the antioxidative
properties of serum samples from ESRD patients during
the hemodialysis (HD) procedure on the basis of different
methods including TAS, the lag times of oxidation of
protein and lipid in serum as well as the carbonyl content
of serum proteins.2. Materials and methods
2.1. Patients
Twenty-two patients (13 males, 9 females, mean age 69.7
years, range 40–90 years) with ESRD who have undergone
chronic HD treatment three times a week for 37.4 months
(range 4–96 months) were included in this study after
having given their informed consent. Blood samples were
drawn from the arterial and venous side of the dialyzer 5 min
after the beginning and 5 min before the end of the dialysis
session. Samples were collected using vacuum tubes, and
aliquots of isolated serum were stored at  70 jC.
The etiologies of the patients renal diseases were diabetic
nephropathy (4), primary glomerulonephritis (5), polycystic
disease (2), plasmocytoma (2), nephrosclerosis (4) and
unknown (5). One patient with nephrosclerosis had a heart
transplantation in 1988, one patient with glomerulonephritis
had a kidney transplantation in 1996. Suffering from chronic
rejection, he came back to dialysis 4 years later. Both
patients are given immunosuppressive therapy.
2.2. Dialysis treatment
During the study, patients were kept on their regular
dialysis regimen. Using Gambro AK 200 machines 16
patients had 4 h HD treatment. The synthetic filters used
were Lundia pro 600R (n = 3), Lundia pro 800R (n = 3),
both gambrane membrane, GFS plus16R (n = 6), a hemo-
phane membrane (Gambro, Lund, Sweden), and F6HPSR
(n = 4), a polysulfone membrane (Fresenius, Bad Homburg,
Germany). Blood flow was 300 ml/min, dialysate flow 500
ml/min. In six patients, hemodiafiltration was performed for
4.5 h with either Polyflux 8 LR (n = 3), a polyamide filter
(Gambro), or Tricea 210 GR (n = 3) a triacetate membrane
(Baxter, Vienna, Austria), with a blood flow rate of 300 ml/
min, and a dialysate flow of 700 ml/min. Blood was drawn
immediately before the inlet of the dialyzer cartridge and
immediately at the outlet of the cartridge. Serum was
prepared and frozen at  70 jC until analysed.
2.3. Antioxidant status
A commercial test kit, Randox TAS, (Dr. Franz Tatzber
KEG, Klosterneuburg, Austria) was used. The assay isbased on the formation of the radical cation of 2,2V-azino-
di-[3-ethylbenzthiazoline sulfonate], (ABTS+) and its reduc-
tion by antioxidants [14,25]. The solutions of the test kit
were prepared according to the instructions and contained
the following constituents: chromogen, consisting of 6.1 AM
metmyoglobin and 610 AM ABTS; substrate, 250 AM
hydrogen peroxide as well as a standard of 1.6 mM trolox.
The assay was not performed as a single time point but as a
kinetic measurement of the lag time of the onset of radical
formation [14,25]. For the assay, 10 Al of sample were
mixed with 250 Al chromogen solution in a cavity of a 96-
well plate. Substrate (50 Al) was added to the mixture and
the measurement of the absorbance at 620 nm was started
immediately. From the kinetic curves of blank (water) and
standard the start time of the reaction was calculated using
the MS Exceln software. In this procedure, slightly different
handling times of different plates are taken into account.
The lag times of the samples were calculated and compared
to the values obtained for trolox. The antioxidant status of
the samples was then expressed as micromolar trolox
equivalents. Measurements were performed in duplicate.
2.4. Fluorescence oxidation assay
The measurements were performed as described else-
where [24]. An ethanolic solution (5 Al) of fluorophore, 1,6-
diphenylhexatriene propionic acid (DPHPA) for protein
labelling and 1-palmitoyl-2-((2-(4-(6-phenyl-trans-1,3,5-
hexatrienyl)phenyl)ethyl)-carbonyl-sn-glycero-3-phospho-
choline (DPHPC) for lipid labelling was added to 150 Al of
an argon-saturated serum sample. For labelling with
DPHPC, the reaction mixture was kept under argon at 37
jC for 12 h, whereas for DPHPA-labelling, the mixture was
incubated under argon at room temperature for 1 h. A 50-
Al aliquot of the labelled sample was diluted with 150 Al of
air-saturated PBS-buffer. Oxidation was started by adding
100 Al of 90 mM 2,2V-azobis-(2-amidinopropane) hydro-
chloride (AAPH, 30 mmol/l final concentration) dissolved
in phosphate buffered saline (PBS) and monitored by
following the time-dependent decrease of the fluorescence
intensity at 430 nm (excitation at 354 nm) at 37 jC using a
fluorescence well-plate reader Perkin-Elmer LS50B and 96-
multiwell plates from Perkin-Elmer (Norwalk, USA). Meas-
urements were performed in triplicate. Lag times for the
DPHPA oxidation are denoted as protein lag times, and
those for DPHPC are denoted as lipid lag times.
2.5. Protein carbonyl content
The carbonyl content of proteins was analysed according
to Buss et al. [26] with slight modifications. Oxidized bovine
serum albumin (BSA) was prepared for standardisation as
described elsewhere [29]. Serum samples and standards were
diluted to give a final protein concentration of 4 mg/ml. The
protein derivatization was carried out in 1-ml tubes with 45
Al of DNPH solution (10 mM dinitrophenylhydrazine; in 6
Table 1
Clinical parameters of the patients before dialysis
Patients (n) 22 Normal range
Sex 13 males/9 females
Age (a) 69.7F 13.2
Total proteins (g/100 ml) 6.5F 0.8 6.6–8.3
Albumin (g/100 ml) 3.2F 0.5 3.5–5.3
Creatinine (mg/100 ml) 6.6F 1.9 0.6–1.3
Urea (mg/100ml) 120F 40 10–45
Uric acid (mg/100 ml) 6.6F 1.1 2.4–5.7
Total cholesterol (mg/100 ml) 180F 60 < 200
Triglycerides (mg/100 ml) 170F 50 < 150
Iron (Ag/100 ml) 37F 19 50–160
Transferrin (mg/l) 1458F 467 2000–3600
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buffer, pH 2.5) added to 15 Al of serum samples or standards.
The mixtures were incubated at 25 jC for 45 min, being
vortexed every 10 min. Then 50 Al of each sample were
added to 950 Al of coating buffer (10 mM PBS, pH 7.4).
Duplicate 100-Al aliquots were added to wells of a white 96-
well chemiluminescence microtiter plate (Greiner, Krems-
mu¨nster, Austria) and incubated overnight at 4 jC. After
washing three times with PBS (PAA, Linz, Austria), 100 Al ofFig. 1. Antioxidative and oxidation parameters of serum during hemodialysis. Bloo
of the HD session, at the inlet (1 and 3) or at the outlet (2 and 4) of the dialyzer. Th
(C) and the carbonyl content of proteins in serum were determined. Bars indicatea 1:10,000 diluted anti-DNP–HRP in 10 mM PBS, pH 7.4
were added to each well and incubated for 1 h at 25 jC. After
washing five times with PBS, the chemiluminescence was
measured on a chemiluminescence reader (Lumistar, BMG,
Germany) after adding 100 Al/well Super Signal Maximum
Sensitivity substrate (Pierce, Rockford, USA).
2.6. Statistics
The indicated data are meansF S.D. Data were com-
pared using a paired t-test. The significance of correlation is
based on linear regression.3. Results
Pre-dialysis serum samples were tested for their clinical
characteristics. Table 1 shows these parameters. The total
protein and albumin content, as well as iron and transferrin
concentrations are slightly below the normal range. Creat-
inine and urea are dramatically increased, as expected. Lipid
and uric acid contents are partly above the recommended
range.d samples were collected at the beginning (1 and 2) and at the end (3 and 4)
e lag times of lipid (A) or protein (B) oxidation, the total antioxidative status
d with * are significantly different from the initial value ( P < 0.001).
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the susceptibility of serum components to damage by free
radicals. As shown in Fig. 1A, the lag time of oxidation of
serum lipids has already significantly decreased during the
first dialyzer passage (114.0F 19.8 vs. 81.5F 18.9 min,
P < 0.001). This value is held almost constant during further
dialysis and becomes slightly lower at the end of the
treatment. Compared to a group of healthy controls analysed
during the same study (n = 9), the lag time of lipid perox-
idation in ESRD patients before HD treatment is not
significantly different (controls 118F 10 min, P= 0.737).
In a similar fashion, the lag times of protein oxidation have
decreased during the dialysis treatment (105.0F 24.6 vs.
72.9F 21.3 min) before and after the first dialyzer passage
(P < 0.001), as is shown in Fig. 1B. Again ESRD patients
are in the control range (110F 7 min, P= 0.999) at the
beginning of the dialysis session. When measuring the TAS,
we found out that ESRD patients have values which are in
the range of a control group (518F 124 vs. 505F 82 AM
trolox in control). However, as shown in Fig. 1C, the TAS
has dramatically decreased during the HD treatment. After
the first dialyzer passage, only about 50% remain. The
serum TAS has even further decreased during the last
passage through the dialyzer (from 250F 83 to 145F 24,
P < 0.001) to a value representing only about 28% of the
initial value.
For both lag times, protein and lipid, good correlations
were found with the TAS values (r = 0.901, P < 0.001 for the
lipid lag time and r= 0.839, P < 0.001 for the protein lag
time) as shown in Fig. 2. The TAS values measured at the
start of the HD treatment correlated well with the urate
content (r= 0.816, P < 0.001) and no significant correlation
of TAS was found with albumin, protein or any other
clinical parameter measured.
The carbonyl content of serum proteins of patients with
ESRD was found to be about fourfold compared to a group
of healthy controls (3.9F 1.1 vs. 0.9F 0.1 nmol/mg,Fig. 2. Correlation of oxidation lag times of lipids (o) and proteins (.) with
TAS values.P < 0.001). Throughout the dialysis procedure this value
did not change significantly.4. Discussion
The antioxidative status of body fluids is a valuable
parameter to assess the sum of antioxidants in these systems
including their synergistic effects. However, the interpreta-
tion of data of the antioxidative status has to be done with
care [16]. Especially concerning the situation of ESRD
patients, the value of the TAS has been questioned and
the results already available are rather controversial. The
differences reported are at least partly due to the differences
in the methods used. Selecting oxidation probes for the
assessment of antioxidative status, one has to take care
regarding the oxidation susceptibility of the probe. As we
have previously shown, the fluorescence probes used in our
study have oxidation susceptibilities very similar to natural
polyunsaturated fatty acids and albumin, respectively [24].
Therefore, these probes can be used as markers for the
oxidation of lipoproteins and aqueous phase components of
human serum.
Using the ABTS-based method, we found no significant
differences in TAS between controls and ESRD patients.
Patients before the HD treatment showed elevated levels of
serum urate but albumin contents below the normal range.
This may explain the lack of a net effect in the TAS which is
predominated by albumin and urate. In parallel, the oxidiz-
ability of water- and lipid-soluble serum components of
controls and patients are in the same range. The dramatic
decrease of the TAS during the HD session is in agreement
with the parallel decrease of the lag time of the protein
oxidation. This could be easily explained by a loss of
ascorbic acid and urate during HD [19,27,28,32], which
synergistically act as antioxidants. Surprisingly, the oxidiz-
ability of lipid-soluble components also increased during the
HD treatment. Published data concerning vitamin E contents
in serum of HD patients range from no difference compared
to controls [5,20,29–32] to lowered values in patients [33–
35]. There is some evidence, however, that vitamin E is
partly lost during the dialysis session [29,36]. Together with
the lost synergistic effect of ascorbic acid, this explains the
decrease in lag times of lipid oxidation.
Our data resulting from different methods are in agree-
ment with the published works reporting an impairment of
the serum antioxidant system during HD treatment [7–9].
The oxidation sensitivity of water-soluble components is
increased during the HD session. On the other hand,
carbonyl content of proteins as a long-term parameter of
oxidative damage is not changed during HD treatment.
However, the content of carbonyl groups is severely in-
creased in patients compared to controls. Therefore, HD
treatment means a contribution to sensitize serum compo-
nents against oxidative stress but the damage itself does not
only happen during HD sessions.
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using different sources of radicals as initiators shows that
measurement of TAS is valuable when following this
parameter within a group of persons. However, comparing
different groups like HD patients with control subjects may
lead to misinterpretations as the increased level of protein
carbonyl groups does not match the normal value of TAS
and lag times before HD.
We have shown that the loss of antioxidants is accom-
panied by an increase in oxidizability of proteins as well as
lipids using oxidation markers which have the same oxidiz-
ability as the natural targets of oxidation [24]. The pro-
nounced decrease in TAS at the beginning of HD treatment
might be due to a response to both a loss of urate and
ascorbic acid, and a particular high oxidative stress during
this first dialyzer passage.
At the end of the session, a further decrease in TAS might
be predominated by a further loss of urate and ascorbic acid.
On the other hand, lag times of lipid and protein oxidation
are decreased only at the beginning of the HD treatment
responding to the antioxidant loss in a different manner or as
a consequence of a massive oxidative stress during the first
few dialyzer passages. It has recently been reported that free
radical production is highest during the first hour of HD
treatment [28]. As a reason for such a first pass effect of
oxidative damage during HD treatment the bioincompati-
bility of the dialyzer membranes and the resulting effects on
leukocyte and platelet activation have been discussed [36–
39]. A lack of change of protein carbonyl groups during HD
treatment combined with a rather high value of carbonyl
content could be interpreted in a delay of carbonyl forma-
tion or in other sources of oxidative stress besides HD
treatment in ESRD patients. The high value of uric acid
content in the serum of HD patients may contribute to their
normal value in TAS and oxidation lag time assay [40].
However, this normal antioxidative behaviour is not suffi-
cient to maintain normal values of protein carbonyl groups.
Our data support the view that supplementation with
antioxidants should be of some benefit for ESRD patients
[41] and the necessity for such a supplementation is highest
at the beginning of the HD session. Vitamin supplementa-
tion is not unusual for HD patients. Vitamin E and ascorbic
acid are the most important antioxidant vitamins used
[35,37,42]. Ascorbic acid, however, is primarily applied
for the improvement of the iron status of HD patients and
the effects on oxidative stress are often not measured [43–
45]. The usefulness of the supplementation of HD patients
with ascorbic acid for the improvement of the antioxidant
defence has even been questioned [46,47]. Vitamin E has
successfully been used to prevent oxidative damage in
ESRD patients [41]. Especially oxidative stress caused by
the treatment of iron deficiency, which could be prevented
by supplementation with vitamin E [30]. Besides oral
supplementation, vitamin E has been used for coating the
dialyzer membranes and this seems to be the most efficient
application [9,27,37,48]. The reason might be that oxidativestress is then suppressed where it originates and that vitamin
E is not only an antioxidant but also enhances the biocom-
patibility of the membranes by its contribution to control
leukocyte activation [37,49].Acknowledgements
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